Medivir’s CEO to BioStock: “I am proud to see our research contribute to a global solution”
Antibiotic resistance is a growing global crisis, increasing the urgency for effective treatments. While Medivir now focuses on cancer therapies, it has a legacy in antimicrobial research. This was highlighted by Infex Therapeutics licensing agreement with Venus Remedies Ltd for the development of MET-X in India – a compound developed from a research program that Medivir outlicensed in 2017. We reached out to Medivir’s CEO Jens Lindberg for a comment.
Read the interview with Jens Lindberg at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/